Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05743842 · ClinicalTrials.gov registry record · NA
TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning
A NA study of Liver Cancer, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT05743842: Active NA study of Liver Cancer, sponsored by M.D. Anderson Cancer Center.
NCT05743842 is a NA study of Liver Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 19 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05743842, a NA study of Liver Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if using the TriNav Infusion System (TriNav catheter) for the injection of the surrogate/test dose during the planning part of the radioembolization procedure and your actual treatment with the radioactive microspheres match each other better than the standard catheter.
Conditions Studied
Interventions
- DEVICE TriSalus™ TriNav™Infusion System
- DIAGNOSTIC_TEST Angiogram
- PROCEDURE Y90-radioembolization procedure
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What the registry record for NCT05743842 still lists
NCT05743842 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 3 interventions - of which TriSalus™ TriNav™Infusion System is the first listed.
NCT05743842 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05743842 about?
NCT05743842 is a clinical study titled "TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning". To learn if using the TriNav Infusion System (TriNav catheter) for the injection of the surrogate/test dose during the planning part of the radioembolization procedure and your actual treatment with the radioactive microspheres match each other better than the standard catheter.
What is the current status of trial NCT05743842?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 19 participants. The study started on 2023-03-14. Estimated completion is 2027-12-31.
What conditions does trial NCT05743842 study?
This clinical trial studies the following conditions: Liver Cancer.
What interventions are being tested in trial NCT05743842?
The interventions under investigation include: TriSalus™ TriNav™Infusion System (DEVICE), Angiogram (DIAGNOSTIC_TEST), Y90-radioembolization procedure (PROCEDURE).
Who is sponsoring clinical trial NCT05743842?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05743842 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05743842's enrollment target sits among peer trials
19 64th of 78 higher than 15 of 78 other Liver Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility Study of CBCT for IGRT in Cancer Patients
RECRUITING · NA
-
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
RECRUITING · NA
-
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
RECRUITING · NA
-
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI